Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi
Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.
Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.
Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.
IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.